GHDX - Genomic Health, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Genomic Health, Inc.

301 Penobscot Drive
Redwood City, CA 94063
United States

IndustryMedical Laboratories & Research
Full Time Employees863

Key Executives

NameTitlePayExercisedYear Born
Ms. Kimberly J. PopovitsChairman, CEO & Pres1.33M143.84k1959
Dr. Steven ShakCo-Founder, Chief Scientific Officer & Interim Chief Medical Officer769.18k341.4k1951
Mr. G. Bradley ColeChief Financial Officer817.44k401.12k1956
Dr. Frederic G. PlaChief Operating Officer786kN/A1959
Mr. James J. Vaughn R.Ph.Chief Commercial Officer628.8k63.8k1963
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.

Corporate Governance

Genomic Health, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.